Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study

Ballem, 1987, Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance, J Clin Invest, 80, 33, 10.1172/JCI113060 Chang, 2003, Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro, Blood, 102, 887, 10.1182/blood-2002-05-1475 Grainger, 2012, Changing trends in the UK management of childhood ITP, Arch Dis Child, 97, 8, 10.1136/adc.2010.184234 Neunert, 2013, Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS), Blood, 121, 4457, 10.1182/blood-2012-12-466375 Butros, 2003, Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis, J Pediatr Hematol Oncol, 25, 660, 10.1097/00043426-200308000-00017 George, 1996, Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology, Blood, 88, 3, 10.1182/blood.V88.1.3.3 2003, Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy, Br J Haematol, 120, 574, 10.1046/j.1365-2141.2003.04131.x Neunert, 2011, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia, Blood, 117, 4190, 10.1182/blood-2010-08-302984 Blanchette, 1994, Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura, Lancet, 344, 703, 10.1016/S0140-6736(94)92205-5 Patel, 2012, Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia, Blood, 119, 5989, 10.1182/blood-2011-11-393975 Bennett, 2006, Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura, Blood, 107, 2639, 10.1182/blood-2005-08-3518 Cooper, 2010, The long-term impact of rituximab for childhood immune thrombocytopenia, Curr Rheumatol Rep, 12, 94, 10.1007/s11926-010-0090-5 Vianelli, 2013, Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years, Haematologica, 98, 875, 10.3324/haematol.2012.075648 Boyle, 2013, Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia, Blood, 121, 4782, 10.1182/blood-2012-12-467068 Kristinsson, 2014, Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up, Haematologica, 99, 392, 10.3324/haematol.2013.092460 Klaassen, 2007, Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools, J Pediatr, 150, 510, 10.1016/j.jpeds.2007.01.037 Erickson-Miller, 2005, Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist, Exp Hematol, 33, 85, 10.1016/j.exphem.2004.09.006 Mitchell, 2014, Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia, Am J Hematol, 89, E228, 10.1002/ajh.23832 Ramaswamy, 2014, Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children, J Pediatr, 165, 600, 10.1016/j.jpeds.2014.03.060 Cheng, 2011, Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study, Lancet, 377, 393, 10.1016/S0140-6736(10)60959-2 Bussel, 2007, Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura, N Engl J Med, 357, 2237, 10.1056/NEJMoa073275 Bussel, 2009, Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial, Lancet, 373, 641, 10.1016/S0140-6736(09)60402-5 Grainger, 2015, Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial, Lancet, 10.1016/S0140-6736(15)61107-2 George, 2009, Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials, Br J Haematol, 144, 409, 10.1111/j.1365-2141.2008.07464.x Klaassen, 2012, Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP), Pediatr Blood Cancer, 58, 395, 10.1002/pbc.23312 Grygiel, 1983, Relationships between plasma theophylline clearance, liver volume and body weight in children and adults, Eur J Clin Pharmacol, 24, 529, 10.1007/BF00609898 Crom, 1994, Pharmacokinetics in the child, Environ Health Perspect, 102, 111, 10.1289/ehp.94102s11111 Brynes, 2015, Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia: Data from the EXTEND study, Am J Hematol, 10.1002/ajh.24011 Ghanima, 2011, Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents, Br J Haematol, 155, 248, 10.1111/j.1365-2141.2011.08845.x Ghanima, 2014, Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up, Haematologica, 99, 937, 10.3324/haematol.2013.098921 Buchanan, 2002, Grading of hemorrhage in children with idiopathic thrombocytopenic purpura, J Pediatr, 141, 683, 10.1067/mpd.2002.128547 Page, 2007, The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP, Br J Haematol, 138, 245, 10.1111/j.1365-2141.2007.06635.x Rodeghiero, 2013, Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group, Blood, 121, 2596, 10.1182/blood-2012-07-442392 Bussel, 2013, Update on the safety and efficacy of EXTENDed treatment with eltrombopag (EPAG) in adults with chronic immune thrombocytopenia (ITP), Blood, 122, 2315, 10.1182/blood.V122.21.2315.2315 Saleh, 2013, Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study, Blood, 121, 537, 10.1182/blood-2012-04-425512 Grainger, 2014, Thrombopoietin receptor agonists in paediatric ITP patients: long term follow up data in 34 patients, Blood, 124, 4206, 10.1182/blood.V124.21.4206.4206 Provan, 2010, International consensus report on the investigation and management of primary immune thrombocytopenia, Blood, 115, 168, 10.1182/blood-2009-06-225565 Bussel, 2011, A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia, Blood, 118, 28, 10.1182/blood-2010-10-313908 Imbach, 2006, Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS), Pediatr Blood Cancer, 46, 351, 10.1002/pbc.20453